131 related articles for article (PubMed ID: 17068155)
1. In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides.
Fujii H; Trudeau JD; Teachey DT; Fish JD; Grupp SA; Schultz KR; Reid GS
Blood; 2007 Mar; 109(5):2008-13. PubMed ID: 17068155
[TBL] [Abstract][Full Text] [Related]
2. Screening of novel immunostimulatory CpG ODNs and their anti-leukemic effects as immunoadjuvants of tumor vaccines in murine acute lymphoblastic leukemia.
Wang J; Zhang W; He A; Zhao W; Cao X
Oncol Rep; 2011 Feb; 25(2):519-29. PubMed ID: 21165566
[TBL] [Abstract][Full Text] [Related]
3. Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses.
Seif AE; Barrett DM; Milone M; Brown VI; Grupp SA; Reid GS
Blood; 2009 Sep; 114(12):2459-66. PubMed ID: 19636062
[TBL] [Abstract][Full Text] [Related]
4. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
[TBL] [Abstract][Full Text] [Related]
5. Interferon alpha and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects.
Brown L; Roda J; Terrell C; Chaudhury AR; Crespin T; Carson WE; Lesinski GB
Surgery; 2006 Aug; 140(2):297-306. PubMed ID: 16904983
[TBL] [Abstract][Full Text] [Related]
6. CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response.
Reid GS; She K; Terrett L; Food MR; Trudeau JD; Schultz KR
Blood; 2005 May; 105(9):3641-7. PubMed ID: 15650062
[TBL] [Abstract][Full Text] [Related]
7. Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients.
Blazar BR; Krieg AM; Taylor PA
Blood; 2001 Aug; 98(4):1217-25. PubMed ID: 11493473
[TBL] [Abstract][Full Text] [Related]
8. Structure-efficacy relationships of immunostimulatory activity of CpG-containing oligodeoxynucleotides on mouse spleen cells.
Du HY; Xia SY; Song HF; Li N; Shang MM; Zou J; Wang QQ; Ou L; Sun X; Ji AG; Tang ZM
Acta Pharmacol Sin; 2007 Oct; 28(10):1637-44. PubMed ID: 17883951
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of innate immune responses by CpG oligodeoxynucleotide in newborn lambs can reduce bovine herpesvirus-1 shedding.
Nichani AK; Mena A; Kaushik RS; Mutwiri GK; Townsend HG; Hecker R; Krieg AM; Babiuk LA; Griebel PJ
Oligonucleotides; 2006; 16(1):58-67. PubMed ID: 16584295
[TBL] [Abstract][Full Text] [Related]
10. Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides.
Takahashi H; Misato K; Aoshi T; Yamamoto Y; Kubota Y; Wu X; Kuroda E; Ishii KJ; Yamamoto H; Yoshioka Y
Front Immunol; 2018; 9():783. PubMed ID: 29720976
[TBL] [Abstract][Full Text] [Related]
11. PyNTTTTGT and CpG immunostimulatory oligonucleotides: effect on granulocyte/monocyte colony-stimulating factor (GM-CSF) secretion by human CD56+ (NK and NKT) cells.
Rodriguez JM; Marchicio J; López M; Ziblat A; Elias F; Fló J; López RA; Horn D; Zorzopulos J; Montaner AD
PLoS One; 2015; 10(2):e0117484. PubMed ID: 25706946
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of oligodeoxyribonucleotides that induce interferon (IFN)-alpha in the pig and the phenotype of the IFN-alpha producing cells.
Domeika K; Magnusson M; Eloranta ML; Fuxler L; Alm GV; Fossum C
Vet Immunol Immunopathol; 2004 Sep; 101(1-2):87-102. PubMed ID: 15261695
[TBL] [Abstract][Full Text] [Related]
13. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice.
Carpentier AF; Chen L; Maltonti F; Delattre JY
Cancer Res; 1999 Nov; 59(21):5429-32. PubMed ID: 10554011
[TBL] [Abstract][Full Text] [Related]
14. Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs.
Olbrich AR; Schimmer S; Heeg K; Schepers K; Schumacher TN; Dittmer U
J Virol; 2002 Nov; 76(22):11397-404. PubMed ID: 12388700
[TBL] [Abstract][Full Text] [Related]
15. CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma.
Warren TL; Dahle CE; Weiner GJ
Clin Lymphoma; 2000 Jun; 1(1):57-61. PubMed ID: 11707814
[TBL] [Abstract][Full Text] [Related]
16. In vivo effects of oligodeoxynucleotides containing synthetic immunostimulatory motifs in weaned piglets.
Zhang L; Tian X; Zhou F
Int Immunopharmacol; 2006 Oct; 6(10):1623-31. PubMed ID: 16919835
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
Chagnon F; Tanguay S; Ozdal OL; Guan M; Ozen ZZ; Ripeau JS; Chevrette M; Elhilali MM; Thompson-Snipes LA
Clin Cancer Res; 2005 Feb; 11(3):1302-11. PubMed ID: 15709202
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo.
Dalpke AH; Zimmermann S; Albrecht I; Heeg K
Immunology; 2002 May; 106(1):102-12. PubMed ID: 11972638
[TBL] [Abstract][Full Text] [Related]
19. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen.
Auf G; Carpentier AF; Chen L; Le Clanche C; Delattre JY
Clin Cancer Res; 2001 Nov; 7(11):3540-3. PubMed ID: 11705874
[TBL] [Abstract][Full Text] [Related]
20. In vivo effects of oligodeoxynucleotides containing synthetic immunostimulatory motifs in the immune response to swine streptococcic septicemia vaccine in weaned piglets.
Linghua Z; Xingshan T; Fengzhen Z
Mol Immunol; 2007 Feb; 44(6):1141-9. PubMed ID: 16911828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
